Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial

Abstract Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patients showed disease progression, they received subsequent novel th...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Richard Labotka, Cong Li, Kwang‐Wei Wu, Nakul Saxena, Xu Yan, Jae Hoon Lee, Meral Beksac
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2022-11-01
Edice:	eJHaem
Témata:	emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor
On-line přístup:	https://doi.org/10.1002/jha2.548
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!